Quick Answer
Pyxis Oncology, Inc. reported Operating Income of -$84.42 million for fiscal year 2025.
Pyxis Oncology, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$84.42M | +5.6% |
| 2024 | -$89.46M | -8.8% |
| 2023 | -$82.20M | +33.4% |
| 2022 | -$123.48M | -77.1% |
| 2021 | -$69.72M | -440.7% |
| 2020 | -$12.89M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$23.46M | +1.2% | -18.8% |
| June 30, 2025 | -$19.75M | +1.4% | +13.8% |
| March 31, 2025 | -$22.91M | -308.8% | +3.5% |
| September 30, 2024 | -$23.75M | +6.3% | -18.6% |
| June 30, 2024 | -$20.03M | -10.5% | -257.4% |
| March 31, 2024 | -$5.61M | +73.3% | +77.9% |
| September 30, 2023 | -$25.35M | +10.7% | -39.9% |
| June 30, 2023 | -$18.12M | +29.6% | +13.5% |
- Pyxis Oncology, Inc. showed an increase of +5.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Pyxis Oncology, Inc.’s operating income has declined by 554.7% (from -$12.89 million to -$84.42 million).
- The most recent figure is from Pyxis Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: